Glutorlix M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake in muscle tissues. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Glutorlix M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. It is important to monitor blood glucose levels regularly to assess therapeutic efficacy and adjust dosage accordingly. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and weight gain. Patients should be educated on recognizing symptoms of hypoglycemia and the importance of adherence to therapy. This medication should be used under medical supervision with periodic evaluation of renal function and glycemic status.